Inflammatory cytokine signatures in epilepsy: distinguishing drug-resistant from drug-responsive patients
Epilepsy & Behavior · 2026-08 · 181 · 111067
DOI: 10.1016/j.yebeh.2026.111067 ↗Kurz gefasst
Fachartikel in der Zeitschrift Epilepsy & Behavior, 2026-08. Verfasst von Ezgi Nazlı und 7 weiteren Autor:innen. Beteiligte Einrichtung: Haydarpaşa Numune Training and Research Hospital, Neurology, Turkey. Electronic address: ezgigoger@gmail.com. Hauptthemen laut MEDLINE: Drug Resistant Epilepsy, Cytokines, Epilepsy. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 65 Literaturangaben. Gefördert von: Sağlık Bilimleri Üniversitesi.
Abstract (Originalsprache)
BACKGROUND: Emerging evidence has positioned neuroinflammation as a central mechanism in the pathogenesis of epilepsy and in the development of drug resistance. Cytokines such as IL-1β, IL-6, IL-8, IL-17, and IL-18 have been implicated in epileptogenesis, yet their clinical significance in distinguishing drug-resistant epilepsy (DRE) from drug-responsive epilepsy (DREsp) remains underexplored. OBJECTIVE: This study aimed to evaluate the serum levels of IL-1β, IL-6, IL-8, IL-17, and IL-18 in patients with epilepsy and to investigate their association with treatment responsiveness and seizure frequency. METHODS: A total of 90 participants were enrolled, including 30 patients with DRE, 30 with DREsp, and 30 age- and sex-matched healthy controls. Serum cytokine levels were quantified using enzyme-linked immunosorbent assay (ELISA). Statistical comparisons, receiver operating characteristic (ROC) analyses, and Jonckheere-Terpstra trend tests were performed to assess intergroup differences and biomarker performance. RESULTS: All five cytokines were significantly elevated in epilepsy patients compared to controls (p < 0.001), and further increased levels were observed in the DRE group relative to the DREsp group. IL-6 and IL-8 showed perfect diagnostic performance in distinguishing epilepsy from healthy individuals (AUC = 1.00), while IL-6 remained highly accurate in differentiating DRE from DREsp (AUC = 0.99). IL-1β demonstrated the strongest correlation with seizure frequency and showed a progressive increase across control, DREsp, and DRE groups. Trend analysis confirmed a significant stepwise elevation of cytokine levels with increasing seizure frequency for all markers. CONCLUSION: Elevated serum levels of IL-1β, IL-6, IL-8, IL-17, and IL-18 in epilepsy-particularly in drug-resistant cases-support the role of neuroinflammation in epileptogenesis and treatment refractoriness. These cytokines may serve as valuable biomarkers for disease severity and potential targets for novel immunomodulatory therapies, especially in patients with DRE who are candidates for non-pharmacological interventions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Haydarpaşa Numune Training and Research Hospital, Neurology, Turkey. Electronic address: ezgigoger@gmail.com.
- Haydarpaşa Numune Training and Research Hospital, Neurology, Turkey.
- Haydarpaşa Numune Training and Research Hospital, Microbiology, Turkey.
- University of Health Sciences, Hamidiye Faculty of Medicine, Biochemistry, Turkey.
Förderung
- Sağlık Bilimleri Üniversitesi
Zitieren
APA
Nazlı, E., Akıncı, T., Çetinkaya, Y., Köklü, H., Özdemir, M. T., Özkan, B. N., Aksaray, S., & Güler, E. M. (2026). Inflammatory cytokine signatures in epilepsy: distinguishing drug-resistant from drug-responsive patients. Epilepsy & Behavior, 181, 111067. https://doi.org/10.1016/j.yebeh.2026.111067
Vancouver
Nazlı E, Akıncı T, Çetinkaya Y, Köklü H, Özdemir MT, Özkan BN, et al. Inflammatory cytokine signatures in epilepsy: distinguishing drug-resistant from drug-responsive patients. Epilepsy & Behavior. 2026;181:111067. doi:10.1016/j.yebeh.2026.111067
BibTeX
@article{Nazl2026,
author = {Nazlı, Ezgi and Akıncı, Tuba and Çetinkaya, Yılmaz and Köklü, Huzeyfe and Özdemir, Melih Tarık and Özkan, Beyza Nur and Aksaray, Sebahat and Güler, Eray Metin},
title = {Inflammatory cytokine signatures in epilepsy: distinguishing drug-resistant from drug-responsive patients},
journal = {Epilepsy & Behavior},
year = {2026},
volume = {181},
pages = {111067},
doi = {10.1016/j.yebeh.2026.111067}
}
EUVIMED